Recall

Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter

Recall from a federal regulator

Headline as published by U.S. Food and Drug Administration (MedWatch) on Oct 9, 2026; collected by the wire Oct 9, 2026, 11:46 AM ET.

Read at U.S. Food and Drug Administration (MedWatch)

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 8, 2026 –Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose.

From U.S. Food and Drug Administration (MedWatch)’s feed

Coverage

  1. U.S. Food and Drug Administration (MedWatch) Federal regulators

    Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method